Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Pfizer (PFE) shares have outperformed the S&P 500 and its industry peers over the past month, but near-term earnings estimates indicate a mixed outlook. While the current quarter's EPS is projected to decline 5% year-over-year, revenue is expected to increase by 2%; full-year revenue is expected to decline slightly. The stock currently holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market, and it receives an 'A' grade for value, indicating it may be undervalued relative to its peers.

Analysis

Pfizer's (PFE) stock has demonstrated recent strength, outperforming both the S&P 500 composite and its Zacks Large Cap Pharmaceuticals industry peers with a +3.7% return over the past month, compared to +0.5% and +2.7% respectively. However, near-term earnings projections present a mixed picture. For the current quarter, EPS is anticipated at $0.57, a 5% decrease year-over-year, with the Zacks Consensus Estimate remaining stable over the last 30 days. The current fiscal year's consensus EPS of $3.06 reflects a -1.6% year-over-year decline, with this estimate seeing a -0.6% downward revision recently. Looking ahead, the next fiscal year's EPS is projected at $3.09, a modest +0.8% increase, with a slight +0.2% upward revision in the past month. Revenue forecasts show a +2% year-over-year increase to $13.55 billion for the current quarter, but project slight declines of -0.6% for the current fiscal year (to $63.25 billion) and -0.5% for the next fiscal year (to $62.92 billion). In its last reported quarter, Pfizer posted revenues of $13.72 billion (-7.8% YoY) and an EPS of $0.92, which significantly beat consensus by +43.75%, although revenues missed by -0.88%. The company has a strong track record of beating EPS estimates in the last four quarters. Despite these mixed signals, Pfizer holds a Zacks Rank #3 (Hold), suggesting its performance may align with the broader market, and scores an 'A' on the Zacks Value Style Score, indicating it is potentially trading at a discount relative to its peers.

Key Decisions for Investors

• Given the Zacks Rank #3 (Hold) and mixed earnings and revenue outlook, investors might consider maintaining current positions rather than initiating new aggressive buys, pending further catalysts.
• Value-oriented investors could find the 'A' grade for Value Style Score attractive, but should weigh this against the flat to slightly negative near-term growth projections for earnings and revenue.
• Closely monitor upcoming earnings reports and any significant revisions to analyst estimates, as these are key drivers for Pfizer's stock performance according to the provided analysis.